Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Progressive Supranuclear Palsy-Pipeline Review, H2 2015

Progressive Supranuclear Palsy-Pipeline Review, H2 2015


  Request for Sample Report

Executive Summary

Progressive Supranuclear Palsy-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Progressive Supranuclear Palsy-Pipeline Review, H2 2015', provides an overview of the Progressive Supranuclear Palsy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Progressive Supranuclear Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Progressive Supranuclear Palsy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Progressive Supranuclear Palsy

and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Progressive Supranuclear Palsy

products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Progressive Supranuclear Palsy

pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Progressive Supranuclear Palsy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy

pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Progressive Supranuclear Palsy Overview 7

Therapeutics Development 8

Pipeline Products for Progressive Supranuclear Palsy-Overview 8

Pipeline Products for Progressive Supranuclear Palsy-Comparative Analysis 9

Progressive Supranuclear Palsy-Therapeutics under Development by Companies 10

Progressive Supranuclear Palsy-Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Progressive Supranuclear Palsy-Products under Development by Companies 13

Progressive Supranuclear Palsy-Companies Involved in Therapeutics Development 14

AB Science 14

AlzProtect SAS 15

Bristol-Myers Squibb Company 16

Prana Biotechnology Limited 17

ProteoTech, Inc. 18

Sellas Inc. 19

TauRx Therapeutics Ltd. 20

Progressive Supranuclear Palsy-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

ASN-561-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

AZP-2006-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

BMS-986168-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

DC-TAB-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

DP-C016-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

masitinib-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

PBT-434-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

PTI-51CH3-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

PTI-51CH3 Backup-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

TPI-287-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

TRx-0237-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

zolpidem tartrate-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Progressive Supranuclear Palsy-Recent Pipeline Updates 47

Progressive Supranuclear Palsy-Dormant Projects 58

Progressive Supranuclear Palsy-Dormant Projects 58

Progressive Supranuclear Palsy-Product Development Milestones 59

Featured News & Press Releases 59

Jul 07, 2014: Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases 59

Dec 10, 2013: Potential Treatment for Parkinson's & Parkinson-Like Diseases with Zolpidem: Sellas Life Sciences Group Holds Global Development & Marketing Rights 59

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

Number of Products under Development for Progressive Supranuclear Palsy, H2 2015 8

Number of Products under Development for Progressive Supranuclear Palsy-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 11

Comparative Analysis by Early Stage Development, H2 2015 12

Products under Development by Companies, H2 2015 13

Progressive Supranuclear Palsy-Pipeline by AB Science, H2 2015 14

Progressive Supranuclear Palsy-Pipeline by AlzProtect SAS, H2 2015 15

Progressive Supranuclear Palsy-Pipeline by Bristol-Myers Squibb Company, H2 2015 16

Progressive Supranuclear Palsy-Pipeline by Prana Biotechnology Limited, H2 2015 17

Progressive Supranuclear Palsy-Pipeline by ProteoTech, Inc., H2 2015 18

Progressive Supranuclear Palsy-Pipeline by Sellas Inc., H2 2015 19

Progressive Supranuclear Palsy-Pipeline by TauRx Therapeutics Ltd., H2 2015 20

Assessment by Monotherapy Products, H2 2015 21

Number of Products by Stage and Target, H2 2015 23

Number of Products by Stage and Mechanism of Action, H2 2015 25

Number of Products by Stage and Route of Administration, H2 2015 27

Number of Products by Stage and Molecule Type, H2 2015 29

Progressive Supranuclear Palsy Therapeutics-Recent Pipeline Updates, H2 2015 47

Progressive Supranuclear Palsy-Dormant Projects, H2 2015 58

List of Figures

Number of Products under Development for Progressive Supranuclear Palsy, H2 2015 8

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 11

Comparative Analysis by Early Stage Products, H2 2015 12

Assessment by Monotherapy Products, H2 2015 21

Number of Products by Top 10 Targets, H2 2015 22

Number of Products by Stage and Top 10 Targets, H2 2015 22

Number of Products by Top 10 Mechanism of Actions, H2 2015 24

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 24

Number of Products by Top 10 Routes of Administration, H2 2015 26

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 26

Number of Products by Top 10 Molecule Types, H2 2015 28

Number of Products by Stage and Top 10 Molecule Types, H2 2015 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

AlzProtect SAS

Bristol-Myers Squibb Company

Prana Biotechnology Limited

ProteoTech, Inc.

Sellas Inc.

TauRx Therapeutics Ltd.

Progressive Supranuclear Palsy, Therapeutic Products under Development, Key Players in Progressive Supranuclear Palsy Therapeutics, Progressive Supranuclear Palsy Pipeline Overview, Progressive Supranuclear Palsy Pipeline, Progressive Supranuclear Palsy Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com